Yelena Janjigian and Norah Lewin Join NBC's Saturday TODAY to Discuss Cycle for Survival's 20th Anniversary
Global Partners Unite to Fund High-Risk, High-Reward Cancer Science - Cancer Grand Challenges
The One Vaccine That Could Save a Generation of Indian Women
$1M AI Accelerator Grant for Ovarian Cancer Research - Ovarian Cancer Research Alliance
Prof. Gevorg Tamamyan Joins the London Global Cancer Week Steering Group
Marty Makary: Approved a MM Drug Just 55 Days After the Application Was Filed
SURE-02 Trial: Neoadjuvant Sacituzumab Govitecan + Pembrolizumab in Muscle-Invasive Bladder Cancer
CART19-BE-02 trial: From Bench to Bedside and Beyond - Resonance
Enter RS and clinical context to view RS category and trial-aligned interpretation for early HR+/HER2- breast cancer.
⚠️ This calculator is intended for ER/PR+ HER2- breast cancer only
TAILORx (Node-negative): Demonstrated that chemotherapy provides minimal to no benefit for most patients with RS 11-25. For patients ≤50 years, some benefit may be seen in RS 16-25.
RxPONDER (Node-positive, 1-3 nodes): Showed that postmenopausal patients with RS 0-25 did not benefit from chemotherapy. Premenopausal patients derived benefit regardless of RS.
RS Categories:
Low
0-10
Intermediate
11-25
High
26-100
